Endo one-ups Valeant with $11.2bn bid for Salix
This article was originally published in Scrip
Executive Summary
Endo International sent Salix Pharmaceuticals a $175 per share bid to acquire the gastrointestinal disease-focused pharma company that trumps the already accepted offer of $158 per share from Valeant Pharmaceuticals, which expects to complete its ongoing tender offer for outstanding Salix shares by 1 April.